Contrast sensitivity improves after brimonidine therapy in primary open angle glaucoma: a case for neuroprotection

D.W. Evans, S.L. Hosking*, D. Gherghel, J.D. Bartlett

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

Aims: To determine the visual outcome following initiation of brimonidine therapy in glaucoma. Methods: 16 newly diagnosed previously untreated glaucoma patients were randomly assigned to either timalal 0.5% or brimanidine 0.2%. Visual acuity, contrast sensitivity (CS), visual fields, intraocular pressure (IOP), blaad pressure, and heart rate were evaluated at baseline and after 3 months. Results: IOP reduction was similar far both groups (p<0.05). Brimanidine improved CS; in the right eye at 6 and 12 cpd (p = 0.043, p = 0.017); in the left eye at 3 and 12 cpd (p = 0.044, p = 0.046). Timolol reduced CS at 18 cpd in the right eye (p = 0.041). There was no change in any other measured parameters. Conclusion: Glaucoma patients exhibit improved CS an initiation of brimanidine therapy.

Original languageEnglish
Pages (from-to)1463-1465
Number of pages3
JournalBritish Journal of Ophthalmology
Volume87
Issue number12
DOIs
Publication statusPublished - Dec 2003

Fingerprint Dive into the research topics of 'Contrast sensitivity improves after brimonidine therapy in primary open angle glaucoma: a case for neuroprotection'. Together they form a unique fingerprint.

  • Cite this